[{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ GSK"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CYP-001","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : FT011 is a novel, first-in-class oral therapy, that acts as a GPCR inhibitor and receives ODD and Fast Track designation. It is being developed for the treatment of systemic sclerosis (scleroderma).

                          Product Name : FT011

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 22, 2024

                          Lead Product(s) : FT011

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which is being evaluated for the treatment of acute graft versus host disease.

                          Product Name : Cymerus MSCs

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 03, 2024

                          Lead Product(s) : CYP-001,Prednisone

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : FT011 is a novel, first-in-class oral therapy, which acts as a GPCR receptor inhibitor. It is being developed for the treatment of systemic sclerosis (scleroderma).

                          Product Name : FT011

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 19, 2024

                          Lead Product(s) : FT011

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceeds will be used for the Phase 3 clinical investigation of the company's PRT120 oral therapy for the treatment of patients with peanut allergy.

                          Product Name : PRT120

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : PRT120

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : SPRIM Global Investments

                          Deal Size : $21.0 million

                          Deal Type : Financing

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs advancing through clinical development for scleroderma (systemic sclerosis). It targets GPCR receptor.

                          Product Name : FT011

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 23, 2023

                          Lead Product(s) : FT011

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.

                          Product Name : IHL-675A

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 26, 2023

                          Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.

                          Product Name : IHL-675A

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 13, 2023

                          Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : FT011 has been designed and developed as potent and selective antagonists to the GPCR target, inhibiting anti-fibrotic and anti-inflammatory pathways. Currently is being investigated for scleroderma.

                          Product Name : FT011

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 02, 2023

                          Lead Product(s) : FT011

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PRT120 is an investigational oral immunotherapy with a novel high dose, rapid escalation dosing regimen for the treatment of peanut allergy. The placebo-controlled trial confirms the effectiveness of PRT120 comprising Prota's rapid escalation dosing regi...

                          Product Name : PRT120

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 02, 2022

                          Lead Product(s) : PRT120

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The PRT120-treated group achieved clinically meaningful improvements in quality of life compared with the placebo group at 12-months post-treatment (p= 0.002).

                          Product Name : PRT120

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 16, 2022

                          Lead Product(s) : PRT120

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank